GaBI Journal-Generics and Biosimilars Initiative Journal JCR impact factor overview
Automatically generated from the journal record shown on this page.
Clarivate JCR impact factor overview
GaBI Journal-Generics and Biosimilars Initiative Journal is listed in this directory with bibliometric information for 2025. It is published by PRO PHARMA COMMUNICATIONS INT. The database records a Journal Impact Factor of 0.200, presented as a Clarivate Journal Citation Reports (JCR)-based metric. Its listed JCR Impact Factor quartile is Q4.
Ranking and quartile
The recorded JCR Impact Factor category rank is 345 out of 352 journals in its listed category. A Q4 designation describes the journal’s position within its subject category; it should not be used as a direct measure of the quality of an individual article.
Citation profile
The record contains 75 total citations, 5 total articles, 5 citable items. The five-year Impact Factor is 0.500, which is 0.300 points above the listed standard Journal Impact Factor. These values use different citation windows and should be interpreted together rather than as a direct trend. The Journal Impact Factor without journal self-citations is recorded as 0.200. The Journal Citation Indicator is listed as 0.070.
Citation half-life
Cited and citing half-life values are not available in the current record.
Journal identifiers and verification
GaBI Journal-Generics and Biosimilars Initiative Journal is identified in this record by print ISSN 2033-6403 and electronic ISSN 2033-6772. Use the ISSN when checking library catalogues, publisher records, indexing databases, or the official Clarivate Journal Citation Reports entry.
Complete journal information
All values below come directly from the database record.
| Journal name | GaBI Journal-Generics and Biosimilars Initiative Journal |
|---|---|
| Abbreviated journal | GABI J |
| Publisher | PRO PHARMA COMMUNICATIONS INT |
| Metric year | 2025 |
| Overall rank | 19,331 |
| ISSN | 2033-6403 |
| eISSN | 2033-6772 |
| Total cites | 75 |
| Total articles | 5 |
| Citable items | 5 |
| Cited half-life | Not available |
| Citing half-life | Not available |
| JCR-based Journal Impact Factor | 0.200 |
| 5-Year Impact Factor | 0.500 |
| Impact Factor without journal self-cites | 0.200 |
| Journal Citation Indicator | 0.070 |
| JCR Impact Factor quartile | Q4 |
| JCR category rank | 345/352 |
| Database record updated |
Frequently asked questions
What is the 2025 JCR-based Journal Impact Factor of GaBI Journal-Generics and Biosimilars Initiative Journal?
The Journal Impact Factor recorded in this directory as a Clarivate Journal Citation Reports (JCR)-based value for GaBI Journal-Generics and Biosimilars Initiative Journal is 0.200 for the 2025 metric year.
What quartile is GaBI Journal-Generics and Biosimilars Initiative Journal?
GaBI Journal-Generics and Biosimilars Initiative Journal is listed in quartile Q4. Quartiles describe a journal’s position within a subject category and should be interpreted within that field.
Who publishes GaBI Journal-Generics and Biosimilars Initiative Journal?
GaBI Journal-Generics and Biosimilars Initiative Journal is listed as being published by PRO PHARMA COMMUNICATIONS INT.
Can a JCR Journal Impact Factor be used to judge an individual article?
No. The Journal Impact Factor is a journal-level citation measure reported in Clarivate Journal Citation Reports. It does not measure the quality, reliability or influence of every individual article published by that journal.
Related journal profiles
Additional records from the same publisher or with a similar listed JCR Impact Factor.